A novel urethral sparing technique for high-dose-rate prostate brachytherapy after transurethral resection of the prostate

被引:0
|
作者
Kunogi, Hiroaki [1 ,2 ]
Cunha, Jason Adam M. [1 ]
Chang, Albert J. [1 ]
Gadzinski, Adam J. [3 ]
Shinohara, Katsuto [3 ]
Hsu, I-Chow [1 ]
机构
[1] Univ Calif San Francisco, Dept Radiat Oncol, 1600 Divisadero St,H1031, San Francisco, CA 94143 USA
[2] Juntendo Univ, Dept Radiat Oncol, Bunkyo Ku, Tokyo, Japan
[3] Univ Calif San Francisco, Dept Urol, San Francisco, CA USA
关键词
Brachytherapy; HDR; Prostate; TURP; Urinary catheter; CANCER; RADIOTHERAPY; TOXICITY;
D O I
10.1016/j.brachy.2017.07.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE: The purpose of this study was to assess retrospectively the variability of the urethral dose optimized using a Foley catheter versus urethral contrast injected using a new modified triple-lumen catheter, in CT-based high-dose-rate (HDR) prostate brachytherapy of posttransurethral resection of prostate (TURP) patients. METHODS AND MATERIALS: At our institution, there were six post-TURP patients with prostate carcinoma between July 2014 and April 2016 who underwent transperineal interstitial HDR brachytherapy (16 needles). A custom modified triple-lumen catheter was placed to inject contrast into the TURP defect. Three-dimensional optimal plans using inverse planning simulated annealing algorithm was generated according to radiation therapy oncology group dose requirements. Alternative plans were retroactively generated for comparison using standard technique based on a Foley catheter as a urethral constraint volume for each patient with the same weighting factors. We compared the dosimetry parameters in each planning using Wilcoxon's ranked sum nonparametric test. RESULTS: The median followup of all patients was 17.5 months. No significant genitourinary or gastrointestinal toxicity was noted using this technique. In the dosimetric analysis, the prostate V-100 values and TURP urethral V100 were significantly different between plans with and without the contrast (V100 [mean]: 92.4 [%] vs. 94.4 [%], p = 0.046; TURP UV100 [mean]: 1.4 cc vs. 2.2 cc, p = 0.028). There were no statistical differences in the mean values of planning target volume V-150%, V(20)0%, and D-90, and each bladder V-75 and rectum (V75). CONCLUSIONS: Post-TURP HDR brachytherapy with urethral contrast showed significantly more volume effect of the TURP defect than that with a Foley catheter alone. Better visualization of the TURP defect should lead to more accurate urethral sparing administration of HDR brachytherapy which is necessary to prevent urethral complication. (C) 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1113 / 1118
页数:6
相关论文
共 50 条
  • [21] Complications and side effects of high-dose-rate prostate brachytherapy
    Martell, Kevin
    Kollmeier, Marisa A.
    BRACHYTHERAPY, 2021, 20 (05) : 966 - 975
  • [22] Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection
    Peddada, Anuj V.
    Jennings, Scott B.
    Faricy, Patrick O.
    Walsh, Richard A., III
    White, Gerald A.
    Monroe, Alan T.
    JOURNAL OF UROLOGY, 2007, 178 (05): : 1963 - 1967
  • [23] The emerging role of high-dose-rate brachytherapy for prostate cancer
    Morton, GC
    CLINICAL ONCOLOGY, 2005, 17 (04) : 219 - 227
  • [24] Salvage high-dose-rate brachytherapy for recurrent prostate cancer
    Kaprin, A. D.
    Ivanov, S. A.
    Karyakin, O. B.
    Obuhov, A. A.
    Biryukov, V. A.
    Borysheva, N. B.
    Sanin, D. B.
    Lepilina, O. G.
    Smolkin, A. L.
    Dem'yanovich, A., V
    Minaeva, N. G.
    Mikhaylovskiy, N., V
    ONKOUROLOGIYA, 2020, 16 (04): : 112 - 119
  • [25] New ambulatory implant technique of high-dose-rate interstitial brachytherapy for prostate cancer
    Yoshida K.
    Nose T.
    Shiomi H.
    Yoshioka Y.
    Fujita Y.
    Kuroda S.
    Yoshida M.
    Takahashi T.
    Kitamura M.
    Akai H.
    Oka T.
    Hosoki T.
    Radiation Medicine, 2006, 24 (8): : 595 - 599
  • [26] Dosimetry modeling for focal high-dose-rate prostate brachytherapy
    Mason, Josh
    Al-Qaisieh, Bashar
    Bownes, Peter
    Thwaites, David
    Henry, Ann
    BRACHYTHERAPY, 2014, 13 (06) : 611 - 617
  • [27] Salvage high-dose-rate brachytherapy for prostate cancer recurrence
    Wojcieszek, P.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S355 - S356
  • [28] High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience
    Jabbari, Siavash
    Hsu, I. -Chow
    Kawakami, Jun
    Weinberg, Vivian K.
    Speight, Joycelyn L.
    Gottschalk, Alexander R.
    Roach, Mack, III
    Shinohara, Katsuto
    BRACHYTHERAPY, 2009, 8 (04) : 339 - 344
  • [29] American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy
    Yamada, Yoshiya
    Rogers, Leland
    Demanes, D. Jeffrey
    Morton, Gerard
    Prestidges, Bradley R.
    Pouliot, Jean
    Cohen, Gil'ad N.
    Zaider, Marco
    Ghilezan, Mihai
    Hsu, I-Chow
    BRACHYTHERAPY, 2012, 11 (01) : 20 - 32
  • [30] High dose rate transurethral brachytherapy as a boost dose for localized adenocarcinoma of the prostate
    Serin, M
    Erkal, HS
    Sak, SD
    Cakmak, A
    Gogus, O
    Akkaya, A
    UROLOGIA INTERNATIONALIS, 1997, 58 (01) : 30 - 33